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Organ-on-a-chip is a microfluidic cell culture model that replicates key organ-specific microarchitecture and
pathophysiology in vitro. The current methods to fabricate these devices rely on softlithography, which is usually
tedious, laborious, and requires adroit users as well as cleanroom facilities. Recently, the use of 3D-printing
technologies for the rapid fabrication of molds for polydimethylsiloxane (PDMS) casting is on the rise. Howev-
er, most of the 3D-printed materials are unsuitable for PDMS casting. To address this issue, we have improved the
existing techniques and introduced a modified protocol for the surface treatment of 3D-printed molds, making
them ideal for repeated long-term PDMS casting. Using this protocol, we have fabricated a simple open well lung-
on-a-chip model to simulate the in vivo environment of airway at air-liquid interface under dynamic condition. To
validate the functionality of the developed chip, Calu-3 cells were cultured in the chip and maintained at an air-
liquid interface. The model demonstrated that the cultured cells replicated the 3D culture-specific-morphology,
maintained excellent barrier integrity, secreted mucus, and expressed cell surface functional P-glycoprotein; all
indicative of a promising in vitro model for permeability assays, toxicological tests, and pulmonary drug delivery
studies. To validate the suitability of this lung-on-a-chip in vitro model, the effects of cigarette smoke extract (CSE)
on Interleukin-6 (IL-6) and Interleukin-8 (IL-8) release from cultured Calu-3 cells were examined. CSE treated cells
showed significantly higher secretion of IL-6 and IL-8 over 24 h compared to the cells treated with both CSE and
Budesonide, an anti-inflammatory drug. Moreover, our results illustrated that CSE reduced the expression of E-
cadherin as an adherent junctional protein. In conclusion, the proposed protocol demonstrated an easy and low-
cost fabrication technique which will allow a biologist with minimal technical skills to rapidly prototype molds for
different/versatile organ-on-a-chip models.1. Introduction
The burden of respiratory diseases throughout the world is on the
rise, with almost 4 million premature deaths from chronic respiratory
diseases every year, indicating a serious health issue (Forum of Interna-
tional Respiratory Societies, 2017). Therefore, there is an urgent need to
develop new respiratory drugs, which require developing better and
physiologically relevant respiratory disease and drug testing models
(Shrestha et al., 2020). The conventional methods used to reproduce the
microenvironment, functions, and physiology of the human lung are two
dimensional (2D) monolayer cell culture and transwell-based immersionngineering, University Technolog
Ebrahimi Warkiani).
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evier B.V. This is an open access acultures (Huh et al., 2011). However, these models do not accurately
replicate in vivo three-dimensional (3D) cellular structure, cell-cell in-
teractions, the air-exposed environment of the alveolar cells, and the
physiological functions at the organ level.
The inability of existing cell culture models to accurately and reliably
model respiratory disease has led to the emergence of microfluidic cell
culture systems. Microfluidic systems precisely replicate the physiolog-
ical conditions required for both basic research and drug development,
enabling drug discoveries through systematic testing (Neuzil et al., 2012;
Azadi et al., 2019). Several microfluidic organ-on-a-chip models repli-
cating the 3D microarchitecture and mechanical and physiologicaly Sydney, Sydney, New South Wales, 2007, Australia.
13 January 2020
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
J. Shrestha et al. Organs-on-a-Chip 1 (2019) 100001features of different organ tissues have been developed (Esch et al.,
2015). However, conventional softlithography techniques used to fabri-
cate organ-on-a-chip devices impose severe limitations on time, geo-
metric complexity, and cost, often requiring a separate cleanroom
facilities and adroit users, as a result of which, impedes the pace of
development and innovation in microfluidic applications. Therefore, a
method for rapid fabricating microfluidic devices with little technical
expertise would be ideal for scientists with little knowledge of
microfabrication.
Recently, additive manufacturing has emerged as an alternative for
the fabrication of microfluidic devices (Vaezi et al., 2013; Erkal et al.,
2014; Bhattacharjee et al., 2016). With further developments in 3D-print-
ing, there has been a significant increase in the utilization of 3D-printed
part as molds to generate PDMS replicas. 3D-printing has superiority over
other techniques of mold fabrication such as micro-milling or laser cut-
ting, enabling higher resolution features and a control over height pa-
rameters (Guckenberger et al., 2015; Condina et al., 2019). Among all 3D
printing methods, stereolithography apparatus (SLA) and digital light
processing (DLP) offer great advantages and are therefore preferred for
microfluidics and biomedical applications (Macdonald et al., 2017). This
allows researchers to rapidly design and alter complex microstructures
without expending large amounts of time or resources. In addition,
3D-printed molds are more adaptable as they can include multiple design
features at different channel heights not possible using conventional
photolithography techniques. However, most of the 3D-printed molds
printed via SLA/DLP techniques are not immediately suitable for PDMS
casting since residual monomers and oligomers on the surface of the
3D-printed parts impede PDMS polymerization. Several groups have
proposed surface treatment methods for 3D-printed molds to make it
suitable for casting PDMS, including ink or lubricant infused coatings,
plasma treatment, salinization, and heat cycling (Waheed et al., 2017;
Chan et al., 2015; Comina et al., 2014; Villegas et al., 2018). Reported
protocols are time-consuming, labor-intensive, and lack reproducibility
(Razavi Bazaz et al., 2019). Although many protocols contain similar
basic parameters such as treatment time, curing temperature, and UV
exposure, these parameters are subject to change according to feature
dimensions. Some groups use the services provided by commercial2
3D-printing companies to manufacture their molds (Park et al., 2019;
Novak et al., 2018). However, these molds can be expensive and have
waiting periods associated with manufacturing and delivery (Ellison
et al., 2016). This type of arrangement does not allow rapid prototyping
to be performed, where quick changes in design parameters are required.
Curing temperature of PDMS on the 3D-printed molds is a vital step that
requires careful optimization to prevent material strain and microstruc-
ture deformation. Therefore, it is crucial to develop an optimized surface
treatment process for 3D-printed molds ensuring long-term cell viability
in the organ-on-a-chip devices.
Herein, we present an enhanced protocol for surface treatment of 3D-
printed molds to fabricate a simple open access lung-on-a-chip design.
The protocol presented here enables the quick fabrication of molds for
long-term use without the development of any cracks or channel dete-
rioration through carefully optimized steps and parameters. This treat-
ment process allows high-resolution repetitive PDMS casting using 3D-
printed molds. The fabricated chip was further optimized by testing
different membranes and ECM coatings for cell growth and extended
viability. The chip allowed the lung epithelial cells to be cultured at an
air-liquid interface under dynamic conditions; the transparency of PDMS
enabled real-time cell visualization and chip monitoring (Fig. 1). Calu-
3 cells are known to highly express the tight junction proteins Occludin
and E-cadherin, which makes it a suitable cell type for analyzing tight-
junction formation and cell barrier functions (Kreft et al., 2015; Haghi
et al., 2010). Mucus production, differentiation, and the expression of
transport proteins are other features of Calu-3 cells, making them useful
for modelling the airway epithelium. Different study groups have already
shown the suitability of this cell line to use it as a respiratory in vitro
model (Zhu et al., 2010; Foster et al., 2000; Florea et al., 2003). Thus, the
Calu-3 cell line was chosen for our lung-on-a-chip device. Using
Calu-3 cells, we demonstrate the versatility of our lung-on-a-chip model
through the assessment of CSE effects and Budesonide treatment on the
secretion of inflammatory markers and cellular expression of the junction
protein E-cadherin. Furthermore, we provide a functional analysis of the
epithelium cell layer generated. The flexibility of direct 3D-printing
utilized in this study will aid the fabrication of novel organ-on-a-chip
designs within a short time frame. The printing process we report hereFig. 1. Microfluidic model of human Lung-on-a-
chip design and fabrication: A) A conceptual
schematic of the experimental setup showing the
human respiratory system B) A cross-section of
human airway tissue. C) 3D printer was used to
fabricate the open well design of the chip model with
upper and lower layers to recapitulate human lung.
D) The top layer contains a central open well for cell
seeding, and an inlet and an outlet for media in the
lower channel. The lower layer includes a channel for
media flow. The porous PC membrane is carefully
placed and aligned between the two layers, where
the cells attach and grow. E) Once the cells were
confluent, the effects of CSE on the cells were
analyzed.
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beyond what is studied here.
2. Materials and methods
2.1. Mold fabrication and surface treatment
The mold was fabricated using a digital light processing (DLP) 3D-
printer, (MiiCraft Ultra 50, MiiCraft, Hsinchu, Taiwan) with a printing
area of 57 32 120mm and XY resolution of 30 μm. The printer pro-
jects a 385–405 nm UV wavelength through the resin (BV-007) on the
resin bath. The design process began with Computer-Aided Design (CAD)
modelling of the required geometries in SolidWorks (2016), after which
designs were exported in an STL file format to the Miicraft printer soft-
ware (MiiCraft 125, Version 4.01, MiiCraft Inc). To enable high-
resolution printing of mold features, the print options were carefully
tailored to each design. Smaller design features required a slice thickness
of 10 μm and a curing time of 1 s per slice, where features were less fine,
slice thicknesses of 30 and 50 μm were used. Considering the size of the
printed molds, a base layer was used to ensure the part adhered to the
picker for the duration of the print. The curing time for the base layer was
set to 24 s. A buffer layer was used to facilitate the transition from the
base layer into the printed part.
To prevent the PDMS from sticking to the 3D-printed mold, surface
treatment of the resin mold is mandatory. We have optimized the surface
treatment method proposed before (Waheed et al., 2017) to shorten the
overall duration, making it suitable for channels with smaller dimensions
and with the ability of repeated casting without affecting the mold
structures. First, the 3D-printed mold was washed with isopropanol (IPA)
followed by high-pressure air drying after the print. After that, the
post-curing of the mold is required for 3min (steps of 10 s). To make sure
that uncured monomers and oligomers on the surface of the mold are
eliminated, the prepared mold was then soaked inside 100% ethanol for
2 h. The surface of the mold must be prepared for the step of an easy
detachment of the PDMS; hence, Oxygen plasma treatment (Basic Plasma
cleaner PDC-002, Harrick Plasma) was carried out for 2min. In the end,
surface of the mold was silanized using trichloro (1H, 1H, 2H,3
2H-perfluoro-octyl) silane (Sigma-Aldrich, Australia) in a desiccator
under vacuum for 1.5 h. The workflow for mold design and fabrication is
illustrated in Fig. 2.
2.2. Flow simulation and diffusion in the channels
To characterize how the microchannel impacts fluid flow and its ef-
fect on the membrane, a 2D model of the proposed design was analyzed
using Comsol multiphysics 5.3a, a commercial CFD package (Bazaz et al.,
2018). To study the effects of fluid flow on the membrane, a coupled
equation in free and porous media flow is mandatory. The flow in the
microchannel is described using continuity and Navier-Stokes equations.
ρðu:rÞu¼r:½  pIþ μðruþðruÞTÞ (1)
r:u¼ 0 (2)
Here, u represents the vector of fluid velocity, ρ denotes fluid density,
μ refers to dynamic viscosity, and p is the pressure. In this study, Brink-

























where εp is porosity, κ is permeability, Qbr denotes mass source or mass
sink, and F equivalents to the external forces. Using an oversimplified
Darcy's law results in the neglection of the viscous effect which arises
from the fluid media. As an alternative, the Brinkman equation was
employed to solve the fluid within the porous media. A hydrophilic
Isopore polycarbonate membrane (Sigma-Aldrich, Australia) is used in
this study. The pore size of the membrane (dpÞ is 0.4 μm while the
porosity ðεp Þ is 15%, and membrane thickness is 10 μm. The membrane
permeability can be calculated via a packed bed model, and its valueFig. 2. Protocol for the surface treatment of the
3D printed resin molds: A) CAD design of the
desired mold using Solidworks. B) The finalized de-
signs are printed using the 3D printer. C). The mold is
then washed with IPA, followed by UV curing. D) and
E). The mold is then dipped in ethanol before plasma
treating. F) and G) Before casting PDMS, the mold is
silanized. Once the PDMS is cured, it is carefully cut
out from the molds to form two slabs. The PDMS
slabs are then cleaned with alternative IPA and
Ethanol washing before being plasma treated,
aligned, and bonded carefully to make a complete
lung-on-a-chip.
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of the cells on the membrane, respectively. The physics-controlled mesh
was used as the domain grid in this study. The normal inflow velocity was
applied at the inlet, while zero static pressure was considered at the
outlet.
2.3. Device fabrication
Following surface treatment of the resin mold, a mixture of PDMS
base and curing agent (ratio of 10:1) was prepared (Sylgard 184 from
Dow Corning, MI, USA) (Fig. 2). The mixture was then degassed in a
desiccator for 20min and poured into the treated molds. The PDMS was
left to cure in the hot air oven for 4–5 h at 45 C. The PDMS layer was
gently lifted off from the mold, trimmed to desired shapes, and holes are
punched for inlets and outlets. The PDMS layers were thoroughly cleaned
with IPA and ethanol, at least three times, followed by air drying between
each wash. Polycarbonate membrane was cut into a square shape, large
enough to cover the central circular well and carefully placed on the
lower PDMS layer. The contact surface of both the upper and lower PDMS
layers was plasma treated for 1min and aligned precisely to ensure
perfect bonding. The bonded chip was then kept in the oven again for 4 h
at 45 C to bond, followed by testing for leakage using food dyes.
2.4. Cell culture
Human airway epithelial cell line, Calu-3 from American Type Cell
Culture Collection (ATCC, Rockville, IN, USA) were cultured in Dulbec-
co's Modified Eagle's medium: F-12 (DMEM: F12) supplemented with
10% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin ( Gibco,
Life Technologies, Australia) and 1% non-essential amino acids (Sigma-
Aldrich, Australia). The chip was sterilized by flushing 70% ethanol
through the channels, followed by hot air drying in the oven. It was then
exposed to UV light in a biosafety cabinet for 30min before the extra-
cellular matrix (ECM) coating. Once the membrane was coated with
ECM, the chip was kept in a humidified incubator at 37 C with 5% CO2
for 2 h before seeding cells. Residual ECM coating in the channels was
removed by passing fresh culture media. After seeding with cells, the
chips were maintained in 37 C and 5% CO2. Themedia in both the upper
and lower channels were replaced daily until the cells were confluent
(day 5). Once the confluency was achieved, the media from the upper
channel was aspirated to allow cells to grow in the air-liquid interface.
The lower channel was then attached to a syringe pump (Fusion 200,
Chemyx Inc.) with a flow rate of 30 μl/h to maintain a dynamic condition
with fresh media flow.
2.5. Cell adhesion to the membrane and ECM coating
Different combinations of membranes and ECM coatings were tested
to guarantee optimal cell growth and the formation of a confluent
monolayer. The different membranes tested were Isopore membrane
Polycarbonate filter (PC) (Merck, Australia), Nuclepore track-etch PC
membrane (Whatman, Australia), Polyester (PE) from transwell cell
culture inserts (Corning Incorporated, Australia), and Millipore from
Millicell culture plate inserts (Sigma- Aldrich, Australia), all with 0.4 μm
pore size. The membranes were first tested without any ECM coating.
Calu-3 cells were seeded at 8000 cells/mm2 and incubated at 37 C, 5%
CO2. Media in both channels were changed every day. The cells were
stained with a working concentration of 1 μg/ml of Hoechst 33342
(Abcam, Australia) and incubated for 15min on day 5. After washing
with phosphate-buffered saline (PBS), it was observed under the micro-
scope to identify the most suitable membrane with the highest level of
cellular attachment. To further enhance the cell attachment, selected
membrane was coated with different ECMs: (i) 5 μg/ml of Fibronectin
(Corning, 356008), (ii) 3 μg/μl of Collagen-I (Col-I) (Corning, 354236),
(iii) 6 μg/μl of Matrigel (Corning, 354234) and (iv) a mixture of 6 μg/μl
Matrigel and 3 μg/μl Col-I. This was followed by incubation for 2 h at4
37 C, 5% CO2, and washing with PBS (Sigma- Aldrich, Australia) to get
rid of excess ECM. Cells were seeded and incubated. The media from both
channels was changed the next day. The cells were then stained with
Hoechst 33342 on day 5 and observed with Olympus Ix73 Inverted Mi-
croscope for cellular attachment to determine the optimal ECM coating
for Calu-3 cell culture.
2.6. Viability and functionality testing of the device
After the selection of the membrane and ECM coating, the following
experiments were conducted in the final chip design.
2.6.1. Cell viability and proliferation
Live/dead cell double staining kit (Sigma-Aldrich, Australia) was
used to distinguish viable cells from non-viable cells. The assay solution
of the stain was prepared by adding 10 μl of Calcein-AM (Solution A) and
5 μl of Propidium Iodide (Solution B) in 5ml of PBS. The cells were
washed with PBS before adding the assay solution. 30 μl of the assay
solution was added to the cell layer in the upper channel and incubated at
37 C for 15min. Olympus Ix73 Inverted Microscope was used to
simultaneously observe live and dead cells.
2.6.2. Mucus staining
The mucus production from the Calu-3 cells in the chip was charac-
terized on day of 3, 5, 7, 9, and 11 of culture by staining the glycoprotein
in the mucus using Alcian blue (1%. (w/v) in 3% (v/v) acetic acid/water
at pH 2.5) (Sigma- Aldrich, Australia). The monolayer of the cells was
washed twice with PBS. After fixing the cells with 4% (v/v) Para-
formaldehyde for 20min, PBS wash was repeated. Finally, 50 μl of Alcian
blue stain was added. The chips were incubated for 15min and washed
multiple times with PBS until the rinsate was clear. Images were obtained
using an Olympus Ix73 Inverted microscope. Depending on the ratio of
red, green, and blue (RGB) from the microscopic images of mucus
staining, data were analyzed to generate a semi-quantitative estimate of
mucus concentration (Haghi et al., 2010). The mean RGB values were
obtained with Image J (v1.52p, NIH) with Color Profile (Dimiter Pro-
danov; Leiden University Medical Centre, Leiden, Netherlands). The
mean RGBB was divided by the total sum of RGB values for each image
(RGBR þ RGBG þ RGBB) to calculate the ratio of blue (RGBB ratio). The
mean RGBB of eight images was used to quantify the secretion of mucus
by the Calu-3 cells for days 3, 5, 7, 9 and 11.
2.6.3. Paracellular permeability of sodium fluorescein (Flu-Na)
The barrier integrity of the cells grown on themembrane was assessed
by using Flu-Na (MW 0.367 kDa, Sigma-Aldrich, Australia) on day 7. The
cell layer in the upper channel was washed with warm PBS (37 C) after
removing themedia from both the channels. The lower channel was filled
with prewarmed PBS, and the cells were incubated at 37 C for 2 h. The
upper channel was filled with 50 μl of flu-Na solution (2.5mg/ml), while
PBS was flushed through the lower channel at 0.5 μl/min for both blank
devices and seeded chips. Samples were collected from the lower channel
every 30min for a total of 120min. The fluorescence of flu-Na present in
each sample was measured in Corning full black clear bottomed 96-well
plates using a fluorescence plate reader (Infinite 200 PRO; TECAN), using
excitation and emission wavelengths of 485 and 520 nm, respectively.
2.6.4. Flow cytometry detection of cell surface P-Glycoprotein
On day 7, the Calu-3 cells were harvested from the membrane of the
chip by trypsinization (TrypLE Express; Gibco). After washing twice with
PBS, the cells were labelled using 20 μl of FITC-anti P-gp (clone17F9, BD
Pharmingen, USA). It was then incubated in the dark at room tempera-
ture for 30min. The cells were washed twice again with PBS before
resuspending them in 200 μl of PBS, spiked with (1 μg/ml) propidium
iodide (PI) (Sigma- Aldrich, Australia). Samples were analyzed by flow
cytometry (FCM) using the CytoFLEX LX (Beckman Coulter, Life Sci-
ences, USA) and CytExpert Software.
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Cigarette smoke extract (CSE) was prepared by a method modified
from a publication (Laurent et al., 1983). One Marlboro Red cigarette
(Philip Morris, Victoria, Australia) was bubbled through 25ml of DMEM
in a T-75 flask at a constant rate, which was considered as 100% con-
centration CSE. The collected CSEwas filtered and diluted to the required
CSE concentrations in the media. Prepared CSE was immediately used
and diluted within 30min. To stimulate Calu-3 cells with a non-toxic
concentration of CSE, first cytotoxicity assay was performed. Briefly,
Calu-3 cells were cultured in 96-well plates were stimulated with serial
dilutions of CSE from 0.0675% to 100%. The cytotoxic concentration of
CSE on Calu3 cells over 48 h was tested using MTS assay kit (Promega,
CellTiter 96® AQueous One Solution Cell Proliferation Assay- Australia).
Then, cells grown on the chip were stimulated with appropriate con-
centration of CSE (the concentration below IC50 (Inhibitory concentra-
tion at 50%). The experiment was categorized into four groups of chips,
and the cells were grown as mentioned previously for 7 days. One group
was first treated with 100 nM Budesonide for 24 h from the lower
chamber and then treated with CSE from the top (Bud-CSE). The second
group was treated with CSE and 100 nM Budesonide at the same time
(CSE-Bud). The third group was only treated with CSE and the fourth
group was the control (no treatment). The lower channel was connected
to a syringe pump and media was collected in a tube for 24 h; this media
was used to measure IL-6 and IL-8 with ELISA technique. The media
collected from the chips were stored at -80 C.
2.8. Enzyme-linked immunosorbent assay (ELISA) for IL-6 and IL-8
The media collected from the chips were stored at 80 C until per-
forming the experiment. After thawing them, the levels of secreted IL-6
and IL-8 were analyzed according to the manufacturer's instructions,
using commercial human IL-6 and IL-8 ELISA kits (BD Pharmingen, San
Diego, CA, USA). The absorbance was read at 450 nm/570 nm using plate
reader (Infinite 200 PRO; TECAN).
2.9. Immunofluorescence staining
To visualize the effects of CSE and Budesonide treatment on the tight
junctions, the Calu-3 cells were assessed by imaging of immunolabelled
stains of tight junction protein, E-cadherin. Images were taken using a
Nikon A1 confocal microscopy (Japan). All immunostaining steps were
conducted at room temperature. The cells were fixed with 4% volume/
volume (v/v) paraformaldehyde (Sigma- Aldrich, Australia) in PBS after
washing three times with PBS. It was then incubated for 15min and
washed with PBS twice. This was followed by permeabilization of the cell
membranes with 0.1% (v/v) Triton X 100 (Sigma- Aldrich, Australia) for
10min and blockingwith 1% (w/v) bovine serum albumin (BSA) (Sigma-
Aldrich, Australia) in PBS for 1 h. After further washing with PBS, cells
incubated with 50mM ammonium acetate in PBS for 10min. Then cells
were washed with PBS and incubated at 37 C with CD324 (E-Cadherin)
monoclonal antibody (10 μg/ml in PBS) (Invitrogen) for 1 h. Rewashing
with PBS was done before adding AlexaFlour 594 goat anti-mouse IgG1
(10 μg/mL in PBS) (Invitrogen, Australia) to incubate for 1 h. After
washing with PBS, the cells were counterstained with 1 μg/mL 40, 6-dia-
midino-2- phenylindole (DAPI) in water for 10min before washing with
PBS. The membrane was carefully cut from the open well of the chip and
mounted on a microscopic glass slide and covered by a coverslip. Care
was taken to prevent curling and tearing of the membrane, and the slides
were stored at 4 C. The slides were viewed the next day using the Nikon
A1 Confocal Laser Microscope with NIS-Elements C Software.
2.10. Statistical analysis
Data were analyzed using IBM SPSS Statistics 25 software (USA). The
ANOVA one-way analysis was used to determine significance (P< 0.05).5
All results are expressed as the mean standard deviation (SD) of at least
three independent determinants.
3. Results and discussion
3.1. Fabrication of the mold and the device
Lung-on-a-chip models typically have closed system designs with
straight channels (Huh et al, 2010, 2012, 2013; Jain et al., 2018; Benam
et al., 2016). Although this allows uniform flow, manipulating cell sus-
pensions and micro-volumes of fluids through microchannel is chal-
lenging. Functional tests such as immunostaining, mucus secretion, and
permeability assays become difficult to perform within a closed design
chip. The open well design of our device allows easy access to the
membrane for uniform coating, cell seeding, fluid manipulation, and
sample collection. Moreover, the open access design allows the cells to be
directly exposed to the CSE, drugs or nanoparticles, making transport or
migration studies more controllable. Multiple open well chambers can be
interconnected to each other to conduct independent as well as parallel
studies. This was first suggested by Blume et al. who developed a similar
open well design compatible with commercially available Transwells to
be interconnected. (Blume et al., 2015). However, this is a complicated
process compounded by the number of components comprising their chip
design. We have effectively simplified the lung-on-a-chip model to
facilitate the on chip cell culture with the potential for multichip in-
terconnections. The simple maintenance and usability of our chip will
allow a person familiar with conventional cell culture methods to
conduct their experiments in a more relevant microenvironment, even
with minimum microfluidic knowledge.
The open well lung-on-a-chip model presented here consisted of an
upper PDMS layer with a large circular well, an inlet, and an outlet on
either side (Fig. 3A). The lower layer comprised of a central chamber
connecting to two straight channels from either side. The thin, porous PC
membrane separated the two PDMS layers. The 3D-printed mold con-
sisted of raised channels to imprint the PDMS surface. Surface treatment
of the mold before casting PDMS is vital for PDMS casting (Chan et al.,
2015). This treatment cures the surface areas of the mold left uncured
from the 3D-printing process. To achieve this, the mold must be free of
any debris, residual monomers or oligomers. The process of silanization
provides a hydrophobic fluorinated monolayer on the 3D-printed mold
that prevents the sticking of the PDMS to the resin mold. This method-
ology allows easy peeling off the PDMS from the mold. Curing PDMS at
45 C for 4–5 h was found to yield the best surface finish for the
3D-printed resin molds. PDMS incubation with the mold at higher tem-
peratures induced the formation of surface fractures within the mold,
negatively impacting the surface finish of the PDMS piece, resulting in
leaking of the bonded device. Hence, it can be reasoned that the tem-
perature has a significant influence on the molds.
This approach of fabricating and treating the 3D-printed resin molds
is a simple, cost-effective, and time-efficient method for producing 3D
microfluidic lung-on-a-chip models compared to the conventional soft-
lithography techniques using silicon wafers. The 3D-printing of the
molds, surface treatment, and chip fabrication can be completed within a
day. This helps to avoid the typically lengthy processing and delivery
time of the commercially manufactured molds. This time reduction is a
result of optimized fabrication steps minimizing the risk of human error.
Thus, the approach presented here enables researchers to rapidly pro-
totype multiple designs of different geometries within a short period. The
molds created can be used repeatedly without concern over the repro-
ducibility between chips. However, despite these advantages, 3D-print-
ing has certain limitations regarding the resolution of printable
features and quality of the surface. For instance, ink-jet type 3D-printing
is an option available for 3D-printing molds to cast PDMS and fabricate
chips (Kamei et al., 2015). Nevetheless, ink-jet 3D-printing can result in
increased surface roughness and may cause altercations in channel
profiles.
Fig. 3. Simulations of fluid flow in
the lung-on-a-chip model: A) Geome-
try and boundary conditions used for
computational modelling. B) Velocity
profile along the length of the micro-
channel. It is evident that the velocity
distribution across the upper channel is
small enough to not negatively impact
attached cells. C) Velocity distribution
along the length of the channel. It is
shown that the velocity profile in lower
channel has a parabolic profile. D) Ve-
locity profile at the upper channel. The
order of velocity is small enough so that
cells are not influenced by shear rate.
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To better quantify the fluid behaviour within the lung-on-a-chip
device, the flow velocity was simulated, as shown in Fig. 3B. The nu-
merical results reveal that the flow exists at a steady-state condition,
and the relative velocity is higher in the lower channel compared to the
upper channel. Streamlines in the lower channel run along the length of
the channel from inlet to outlet and shows that the velocity profile in
the lower channel is parabolic (Fig. 3B) while, in the upper channel,
fluid is driven from the lower channel across the porous membrane
before exiting from the membrane. These results indicate that fluid can
traverse the membrane, passing between the upper and lower channels
continuously. Thus, the velocity distribution along the length of
membrane is calculated and illustrated in Fig. 3D. According to the
value of velocity in the upper channel, the effect of media flow on the
cells growing on the membrane is negligible. This allows the secreted
molecules from the cells cultured on the membrane to remain undis-
turbed in the interstitial fluid since the flow of media is limited to the
lower surface of the cell layer (Nalayanda et al., 2009; Walker et al.,
2004). This was further validated by mucus staining performed over
several days.3.3. Cell adhesion to the membrane and ECM coating
To determine the optimal membrane and ECM coating combination
to support the adhesion and growth of the Calu-3 cells in the device,
several types of membranes and ECMs were tested. We evaluated the
results based on the cell adhesion and area coverage by cells. Chips were
seeded with 8000 cells/mm2 which ensured a viable cell population
covering a large area. Based on these findings, 8000 cells/mm2 seeding
density was used for all subsequent experiments in this study. On the fifth
day of incubation, the chip was observed for cell attachment; to help
confirm cellular attachment, the cells were stained with Hoechst
(Fig. 4AI). The PE membrane consistently showed large empty areas with
minimal cellular attachment. In comparison the Millipore membrane
provided greater cell attachment, but the membrane with the most6
consistent cell attachment was PC (Merck, Australia). Therefore, for
further experiments on ECM coatings, PC (Merck, Australia) membranes
were used.
To identify which ECM coating achieved the highest level of cellular
attachment, cell viability and the formation of a monolayer, multiple PC
membranes were coated with Fibronectin, Collagen-I, Matrigel, and a
mixture of Matrigel and Collagen-I. A mix of 6 μg/μl Matrigel and 3 μg/μl
Col-I was selected based on findings suggested by Humayun et al. (2018).
Seeded membranes were then incubated and washed with PBS to remove
all detached and dead cells. The cells were then stained with Hoechst to
compare the results of different ECM coatings on day 5 (Fig. 4AII).
Fibronectin coated chips had few attached cells, with the majority of the
membrane left unoccupied. The membrane coated with Collagen-I had
comparatively more cells attached but still had large sections void of any
cells. Matrigel coating had a significantly larger proportion of cells
attached to the membrane with few empty spots. The coating with the
highest cell coverage was the mixture of Matrigel and Col-I, similar to the
findings of HumayunM., et al. Fig. 4AII illustrates the distribution of area
coverage by cells in each membrane and ECM scenario tested. The most
confluent monolayer can be observed in the combination of collagen and
Matrigel on a PC membrane.3.4. Testing the functionality of the lung-on-a-chip model
3.4.1. Live and dead staining
To confirm the cell viability, cells grown in the chips for 3, 5, and 7
days were stained with live and dead staining kit. The aimwas to note the
day for the cells to get fully confluent with minimal dead cells in the chip.
The chip was then connected to a syringe pump to provide a constant
stream of media in the lower channel, while the cells were cultured at the
air interface in the upper channel by removing the media. The number of
live cells increased gradually from day 3 and were confluent by day 5. On
day 5, the media on the upper channel was removed to create an air-
liquid interface. The cells were viable and growing well on day 7 i.e.,
after 48 h at the air-liquid interface (Fig. 4C). Thus, we decided to
perform further characterization of the cell layer lung-on-a-chip model
Fig. 4. Calu-3 adhesion in the chip: A) I. Cell adhesion to the membrane A-II Selection of coating ECM on the PC membrane: Once the PC membrane was
identified as the suitable membrane, different ECM coating was used to identify the optimal ECM for cell attachment and proliferation. All cells were stained with
Hoechst stain. (Scale: 100 μm) B) Cell viability: Live and dead staining of the cells in the chip on day 7 (Scale: 100 μm).
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results showed that the chip was able to grow and maintain a viable cell
population up to 2 weeks.
3.4.2. Mucus secretion
Airway mucus is an extracellular gel, which traps inspired toxins and
carries them out of the lung through ciliary beating and coughing,
making the lungs highly defensive to environmental harm (Fahy and
Dickey, 2010; Knowles and Boucher, 2002). Calu-3 cells contain sub-
mucosal glands, which are a source of airway surface liquids such asFig. 5. Mucus staining of Calu-3 in the chip A) Microscopic images of mucus stain
days of Calu-3 grown in the chip (Mean SD, n¼ 8) (Scale: 100 μm).
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mucus, making it an optimal cell line for assessing cellular functionality
(Knowles and Boucher, 2002). Alcian blue staining enabled the detection
of secretedmucus in Calu-3 cells (Haghi et al., 2010; Inglis et al., 1998). A
film of mucus was seen on the surface of the Calu-3 cell layer after day 3
(Fig. 5A). The representative microscope images shown indicate an in-
crease in mucus secretion over the 7 days of growth, as the blue staining
became progressively darker, covering more areas of the membrane. The
amount of mucus produced over several days, measured as an RGBB ratio
(Fig. 5B), increased with time.
Here, mucus secretion is used as an indicator of a differentiated celling of Calu-3 cells at I. Day 3 and II. Day 7 B) A plot of RGBB ratio across several
J. Shrestha et al. Organs-on-a-Chip 1 (2019) 100001layer to goblet cells (mucus-producing cells) and, therefore, by extension,
the physiological functionality of cells (Haghi et al., 2010). The RGBB
value is an indirect measure of mucus production and shows variations in
mucosal secretion, which enables a comparison of mucus secretion across
several days. Since the secretion increased with time, it can be concluded
that the cell layer grown in the chip represented physiological
functionality.
3.4.3. Sodium fluorescein permeation
The permeability of the cell monolayer was tested by studying the
permeation of sodium fluorescein (flu-Na) across the cell monolayer.
There was a significant decrease in the permeability values in the
cultured devices as compared to the blank devices (Fig. 6A). The signif-
icant difference in flu-Na concentration indicates a barrier formation by
the cell junctions in the monolayer of cells growing on the membrane.
This ability of the model to culture cells at an air-liquid interface and
develop a tight barrier against flu-Na permeation, is another physiolog-
ical function of respiratory epithelial cells.
3.4.4. Cell surface P-gp expression
Transport proteins are integral transmembrane proteins involved in
the pharmacokinetics of many drugs (Haghi et al., 2010). They play a
crucial role in the absorption of the drugs, its distribution, and elimina-
tion of waste metabolites; as such they are vital in maintaining the
pharmacological barrier integrity throughout the body. P-gp is a plasma
membrane glycoprotein, magnesium (Mg2þ)-dependent ATPase, and is a
predominant drug transporter protein (Bebawy et al., 2001). P-gp is
physiologically expressed on the surface of respiratory epithelial cells
(Madlova et al., 2009). Commonly used drugs for treating respiratory
diseases have shown interaction with P-gp, making it relevant forFig. 6. A) Flu-Na permeation: Transport of flu-Na from apical to basolateral in blan
the P-gp expression in Calu-3 cells cultured in the chip on different days: The ex
P-gp expression by Calu-3 cells on day 7: I. Control group with no staining; II. C
Samples stained with both FITC-anti P-gp and PI.
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respiratory drug transport studies (Forbes and Ehrhardt, 2005). The P-gp
expression of the cultured Calu-3 cells in the chips was analyzed using
flow cytometry by direct immunolabelling. In comparison with the iso-
type control, chip grown cells displayed P-gp expression, which increased
gradually over time (Fig. 6B). Nevertheless, this result further validates
the functionality of Calu-3 cells in our lung-on-a-chip model and favours
the suitability of the model to be used for in vitro pulmonary drug
transport studies.3.5. Effects of CSE on IL-6 and IL-8 production from cultured Calu-3 cells
Cigarette smoke contains over 4000 individual chemicals, which are
noxious and carcinogenic (Burns, 1991). These chemicals, once depos-
ited on the surface of the airways, absorb across the alveolar-capillary
membrane to be circulated into the blood. The inflammatory response
contributes to the structural and functional changes in the lung, leading
to their destruction and subsequently the development of lung diseases.
Cigarette smokers are associated with altered levels of inflammatory
cytokines secretion in their bronchoalveolar lavage (BAL) (Maestrelli
et al., 2001; Mikuniya et al., 1999). IL-8 is a potent chemoattractant for
neutrophils and eosinophils; released by phagocytes and various tissue
cells when exposed to inflammatory stimuli (Baggiolini and Clark-Lewis,
1992). IL-6 is a pro-inflammatory cytokine secreted by epithelial cells
and macrophages in the airways (Mikuniya et al., 1999). Several studies
have reported increased levels of IL-6 and IL- 8 in the BAL and induced
sputum obtained from smokers (Mikuniya et al., 1999; Mio et al., 1997).
Budesonide, a glucocorticoid, has been successfully used in asthma and
inflammatory disorders like COPD (Lung and Institute, 2002; Keatings
et al., 1997). The cytotoxicity assay showed that 10% CSE was not toxic
to the cells (Supplementary Materials). Thus, 10% CSE was used for thek and seeded chips on day 7 of culture (n ¼ 3, * ¼ p < 0.01) B) Comparison of
pression of P-gp increased with days. C) Flow cytometry results of measuring
ontrol group stained with FITC-anti P-gp III. Control group stained with PI IV.
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(p< 0.05) was observed with CSE treatment. The cells treated with 10%
CSE only released significantly higher amounts of IL-6 (p< 0.01) and IL-8
(p< 0.05) over 24 h compared to cells treated with both CSE and
Budesonide (Fig. 7A). The CSE-Bud and Bud-CSE group had lower
amounts of IL-6 and IL-8 secretion, indicative of the anti-inflammatory
effects of Budesonide (Keatings et al., 1997; Confalonieri et al., 1998).
The increased secretion of IL-6 and IL-8 on exposure to CSE are in sub-
stantial agreement with previous studies (Mikuniya et al., 1999; Mio
et al., 1997; Wang et al., 2000). The capability of our model to success-
fully replicate the effects of CSE and Budesonide makes it a suitable in
vitro model for toxicological and inflammatory studies.3.6. Effects of CSE on cellular expression of E-cadherin
The junctional complexes, tight junctions, and adherens junctions
maintain the epithelial cell integrity (Jang et al., 2002). The tight junc-
tions are located apically and form a barrier controlling paracellular
permeability of ions and solutes, while the adherens junctions hold the
cells together through calcium-dependent adhesion molecules (Tsukita
et al., 2001; Zihni et al., 2016). E-cadherin, an adherent junction protein,
is observed in the cell membrane or cell-cell junctions. It is required for
proper localization of essential tight junctional proteins like claudin-1
and 4, and ZO-1, into junctions to maintain a correct and intact tight
junction formation (Tunggal et al., 2005). The loss of this cell trans-
membrane protein destabilizes the epithelial cell integrity, leading to
dissociation between neighbouring cells and reduced its polarity (Willis
and Borok, 2007). Cigarette smoke exposure has been associated with the
disruption of the airway epithelium barrier integrity and increased
permeability (Rusznak et al., 2000). Also, the disruption of the inter-
cellular junctional integrity in the absence of tight junction proteins
when exposed to CSE has been previously noted (Schamberger et al.,9
2014). To confirm the effects of CSE treatment on the expression of the
surface protein, E-cadherin, the Calu-3 cells were stained with mono-
clonal antibodies against E-cadherin and observed with a confocal laser
scanning microscope. Single confocal slices are shown in Fig. 7 B illus-
trate the differentiated tight junction and nucleus stained regions. The
cells grown in absence of CSE maintained their morphology and strongly
expressed E-cadherin protein. However, treatment with 10% CSE for
24 h, showed reduced expression of the epithelial marker. Similarly, the
cells treated with both CSE and Budesonide also had a slightly reduced
expression of the E-cadherin. The results agree with earlier findings of
the effects of CSE on the barrier integrity and E-cadherin expression in
cultured airway epithelial cells (Schamberger et al., 2014; Oldenburger
et al., 2014; Xi et al., 2000). This re-affirms the validity of our micro-
fluidic lung-on-a-chip model as a functional platform to conduct pul-
monary studies.
4. Conclusion
Asimple fabrication techniqueof lung-on-a-chipdevices using surface-
treated 3D-printedmolds has been proposed in this paper. The fabrication
technique allows the chip to be fabricated in less than a day, and themolds
can be used for repeated PDMS casting. Thus, the technique is simple,
robust, and cost-effective. Validation of our design was conducted by
investigating the effects of CSE on the production of inflammatory
markers, IL-6, and IL-8, along with effects on cellular expression of
adherent junction protein, E-cadherin. CSE augmented the release of IL-6
and IL-8 from the epithelial cells cultured within a lung-on-a-chip model.
The budesonide treatment helped to reduce the effects of CSE on the
release of both IL-6 and IL-8. Moreover, our results show that the CSE
disrupted the airwayepithelial barrier by affecting the junctional proteins.
This result is supportive of the findings of numerous studies suggesting
that cigarette smoke is the precursor of inflammatory response andFig. 7. Effects of CSE on cultured Calu-3 cells in
the chip: A) IL-6 and IL-8 release from Calu-3 cells
in response to CSE: The cells were cultured until
confluency in the upper channel and were treated
with 10% CSE. Normal media alone or media con-
taining 100 nM Budesonide was flown at 30 μl/h and
collected in a tube. After 24 h of incubation, the
collected media was later assessed for IL-6 and IL-8
by ELISA. B) Changes in the E-cadherin expres-
sion: Imaging of immunofluorescence-stained Calu-
3 cells cultured in the absence of CSE showed strong
surface expression of E-cadherin. The Bud-CSE group
and CSE-Bud group both showed a slight reduction in
expression of the epithelial marker, E-cadherin.
However, with treatment with 10% CSE for 24 h, the
expression of E-cadherin was reduced significantly.
E-cadherin staining is shown in green, and DAPI
staining is shown in blue. Scale bar: 50 μm. White
arrows indicate disrupted tight junctions after treated
with 10% CSE. Data are expressed as mean  SD (n
¼ 3). * indicates p < 0.05, ** indicates p < 0.01. (For
interpretation of the references to colour in this
figure legend, the reader is referred to the Web
version of this article.)
J. Shrestha et al. Organs-on-a-Chip 1 (2019) 100001contributes to the development of smoke-related respiratory diseases.
Therefore, these results confirm that our design produces similar results to
the in vitro static experiments but in a dynamic condition which has far
more comparability to the real physiological conditions. The model
developed using 3D-printed molds was able to maintain excellent barrier
integrity, expressed cell surface functional P-gp, and secretion of mucus
layer, providing a platform for permeability assays, transport mecha-
nisms, and pulmonary drug delivery studies. Also, the ability to rapidly
prototype these molds with little technical skills makes organ-on-a-chip
modelling accessible to a broad group of researchers.Declaration of competing interest
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